The antitumor efficacy of the combination therapy of OV-OX40L/IL12 and TILs was confirmed in the second oral cancer PDX model (OC4 PDX), with all mice receiving the combination therapy of OV-OX40L/IL12 and TILs displaying progressive tumor shrinkage, while all animals in the other groups showed tumor progression 4 weeks after treatment (Figure S8). This evidence concerns the gene TNFSF4 and lip and oral cavity carcinoma.